KeyBank's SBA Loans Provide Capital To Fuel Small Business Growth
KeyBank's Small Business Administration (SBA) specialists work closely with business owners offering tailored and smart financing solutions aligned to their goals
CLEVELAND, OH / / May 19, 2025 / Starting a small business takes a vision and resources that not every entrepreneur has at their fingertips. As the foundation of our communities, small businesses often require a full suite of financial of solutions* to meet their needs. That's why KeyBank's Small Business Administration (SBA) Specialists take the time to understand each business owner's needs and create tailored financial solutions that help them achieve their goals
KeyBank's SBA Loans Put Businesses First
As one of the nation's top SBA Preferred Lenders for over 20 years1, KeyBank offers a full suite of SBA loan programs, including the SBA 7(a) loan, the SBA 504 loan, the SBA Express Loan Program. We work closely with entrepreneurs to identify the right loan solution that fits their business goals, whether that's navigating ownership transitions or securing* growth financing to purchase new equipment, facilities, or inventory.
With a fully dedicated SBA lending platform, from loan origination through closing, KeyBank ensures that business owners can efficiently access the capital* they need while receiving the highest level of service from our specialized SBA lending staff. The goal is to provide custom support to make accessing capital easier, faster, and more personal for small business owners at every stage of growth.
"Getting capital* into the hands of more small businesses is a critical part of KeyBank's purpose of helping the communities we serve thrive," said Jim Fliss, National Manager of KeyBank's SBA Program. "These small businesses are the backbone of our economy and they have shown such resiliency in recent years. We are committed to helping more small businesses take advantage of the benefits the SBA lending programs have to offer."
KeyBank's SBA Loans Make Real Impact
SBA lending programs are pivotal to meeting the evolving needs of small business owners, and KeyBank's impact is evident in its reach. Since 2015, KeyBank has provided $2.8 billion in SBA-guaranteed financing to thousands of small business owners, with $1.2 billion financed within just the past four years.2 $11 billion in critical funding has also been dispersed through SBA-approved PPP loans.3
Visit www.key.com/small-business/banking/loans-lines/sba-loan-programs.htmlfor more information.
KeyBank's Commitment to Small Businesses
KeyBank is committed to investing in the communities we serve by helping the businesses that power them thrive, and Key's continued growth reflects the real impact of that commitment.
Complementing our industry-leading SBA offerings, Key is proud to be a true relationship bank that offers holistic financial solutions including treasury*, merchant*, and wealth management services for the company, the entrepreneur and the company employees.
By emphasizing an advice-driven philosophy, KeyBank aims to strengthen relationships with business owners and help them achieve long-term success in an increasingly complex financial landscape. To learn more about how KeyBank can serve your business, visit www.key.com/smallbusiness.
CFMA #250513-3215228
1Source: U.S. Small Business Administration (SBA) from August, 1997 to October, 2024.
2 Source:Statistics released by the U.S. Small Business Administration (SBA) October, 2024 for total approved loans through the SBA's 7(a) lending program during the federal fiscal year ending 9/30/2024.
3 Source: KeyBank Doubles SBA 7(a) Lending Volume, Remains a Top Small Business Lender in the Country
*All credit products, merchant services, treasury products are subject to collateral and/or credit approval, terms, conditions, availability and subject to change.
SBA loans subject to SBA eligibility.
View additional multimedia and more ESG storytelling from KeyBank on 3blmedia.com.
Contact Info:Spokesperson: KeyBankWebsite: https://www.3blmedia.com/profiles/keybankEmail: info@3blmedia.com
SOURCE: KeyBank
View the original press release on ACCESS Newswire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Fulton County chairman says he was 'disinvited' from White House meeting
The Brief Fulton County Chairman Robb Pitts says he was disinvited from a White House meeting after already traveling to Washington, D.C., costing taxpayers nearly $2,000. Pitts questioned why he was disinvited while other Fulton County commissioners remained on the guest list; the White House cited seating capacity limits. Both Pitts and Henry County Commission Chair Carlotta Harrell, who was also disinvited, are Democrats, raising questions about whether politics played a role. FULTON COUNTY, Ga. - A scheduled White House meeting for local leaders has turned into controversy after Fulton County Commission Chairman Robb Pitts said he was unexpectedly disinvited — a claim the White House disputes. What they're saying Pitts was already in Washington, D.C., ahead of Tuesday's meeting when he said he received an email on Sunday notifying him that he was no longer invited. The email, according to Pitts, read: "We regret to inform you that due to circumstances beyond our control, we are no longer able to welcome you to the White House. We appreciate your understanding." Pitts' travel expenses — just under $2,000 for airfare and hotel, according to the county — were already incurred by taxpayers before the cancellation. He had planned to meet with officials including the head of the Small Business Administration and former U.S. Senator Kelly Loeffler. Pitts said his top priority was to advocate for Fulton County's grants and ensure they are not cut. Fulton County, Georgia's most populous county, was still represented at the White House event by other commissioners from both political parties. However, Pitts questioned why he, as chairman, was disinvited while his colleagues remained on the guest list. What we know An email provided by the county showed that after Pitts submitted his RSVP on Sunday, the White House opened additional invitations to other political leaders. Henry County Commission Chair Carlotta Harrell also received a notice that she could no longer attend. Harrell, however, had not yet traveled to Washington, meaning no expenses were incurred for Henry County. The White House Intergovernmental Affairs Office initially did not provide an explanation, but later a White House official stated the disinvitations were due to seating capacity being maxed out. When asked if he thought it was a mistake or political, Pitts said he thinks it is political. Both Pitts and Harrell are Democrats. There have been unconfirmed reports that other counties were affected by similar disinvitations, but no further details have been verified.
Yahoo
3 hours ago
- Yahoo
Ascletis Announces Phase III Trial of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne, Meets All Endpoints
Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated statistically significant and clinically meaningful improvement compared to placebo in all primary, key secondary, and secondary endpoints Denifanstat demonstrated a favorable safety and tolerability profile Denifanstat was 98% and 178% more effective than U.S. Food and Drug Administration (FDA)-approved sarecycline and doxycycline with regard to placebo-adjusted percent treatment success, respectively, 18.6% for denifanstat versus 9.4% for sarecycline, 18.6% versus 6.7% for doxycycline Denifanstat was 60% more effective than FDA-approved clascoterone cream with regard to placebo-adjusted percent treatment success, 18.6% for denifanstat versus 11.6% for clascoterone cream, respectively The exceptional efficacy of denifanstat coupled with its favorable safety profile in the Phase III trial provides a potential major break-through for the treatment of acne HONG KONG, June 3, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that denifanstat (ASC40), a first-in-class, once-daily oral small molecule fatty acid synthase (FASN) inhibitor, meets all primary, key secondary, and secondary endpoints in the Phase III clinical trial for the treatment of moderate to severe acne vulgaris (NCT06192264). The Phase III clinical trial was a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of denifanstat once-daily oral tablet in 480 patients with moderate to severe acne vulgaris. Patients were enrolled and randomized into one active treatment arm and one placebo control arm at the ratio of 1:1 to receive 50 mg denifanstat oral tablet once daily or matching placebo for 12 weeks. Baseline characteristics were well balanced between denifanstat and placebo arms. Table 1 summarizes some of baseline characteristics. Primary, key secondary, and secondary endpoints can be found in Table 2. Primary endpoints included the percent treatment success (defined as an Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) with at least a 2-point decrease in IGA from baseline at week 12), the percent reduction from baseline in total lesion count, and the percent reduction from baseline in inflammatory lesion count. At week 12, percent treatment success was 33.2% compared to 14.6% for placebo, p<0.0001, percent reduction from baseline in total lesion count was 57.4% compared to 35.4% for placebo, p<0.0001, and percent reduction from baseline in inflammatory lesion count was 63.5% compared to 43.2% for placebo, p<0.0001. The key secondary endpoint, percent reduction from baseline in non-inflammatory lesion count at week 12, was 51.9% compared to 28.9% for placebo, p<0.0001. Denifanstat demonstrated a favorable safety and tolerability profile following 12 weeks of once-daily oral administration at 50 mg. The incidence rates of treatment-emergent adverse events (TEAEs) were comparable between denifanstat and placebo. No incidence rates of TEAEs related to study drug in any category exceeded 10%. Only two categories of TEAEs had an incidence rate of more than 5% (6.3% dry skin in denifanstat-treated patients versus 2.9% in the placebo group; 5.9% dry eye in denifanstat-treated patients versus 3.8% in the placebo group). All denifanstat-related adverse events (AEs) were mild or moderate. There were no denifanstat-related grade 3 or 4 AEs and no denifanstat-related serious AEs (SAEs). No deaths were reported. The mechanisms of action of denifanstat for the treatment of acne are (1) direct inhibition of facial sebum production, through inhibition of de novo lipogenesis (DNL) in human sebocytes; and (2) inhibition of inflammation, through decreasing cytokine secretion and Th17 differentiation. Denifanstat's unique mechanism of action directly reduces one of the main underlying causes of acne which is the overproduction of sebum. This makes denifanstat unique as most other acne treatments do not treat the underlying cause of the condition. "We are extremely pleased with the topline results of our Phase III trial. Denifanstat tablets demonstrated impressive efficacy beyond treatment success, showing significant reductions in total lesion count, inflammatory lesion count, and non-inflammatory lesion count. We are excited to be submitting this innovative treatment with the China National Medical Products Administration (NMPA) soon." said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis. Table 3 highlights the excellent efficacy of denifanstat in a non-head-to-head comparison to other commonly used oral and topical acne treatments. Denifanstat demonstrated its exceptional efficacy across multiple key metrics compared to sarecycline, doxycycline and clascoterone cream. With regard to the placebo-adjusted percent treatment success and the placebo-adjusted percent reduction from baseline in inflammatory lesion count, denifanstat was 98% and 30% more effective than sarecycline, respectively, 178% and 178% more effective than doxycycline, respectively, and 60% and 59% more effective than clascoterone cream, respectively. With regard to the placebo-adjusted percent reduction from baseline in total lesion count, denifanstat was 189% and 85% more effective than doxycycline and clascoterone cream, respectively. With regard to the placebo-adjusted percent reduction from baseline in non-inflammatory lesion count, denifanstat was 411% and 102% more effective than sarecycline and clascoterone cream, respectively. Denifanstat has the potential to be a first-in-class, once-daily, oral acne therapeutic, potentially offering both exceptional efficacy and patient compliance with a favorable safety and tolerability profile. Compared to other oral acne treatments, denifanstat provides outstanding efficacy with excellent safety. There is no potential for antibiotic resistance or off target effects which can occur with tetracycline derivatives and no reported denifanstat-related severe AEs such as hepatotoxicity, hearing impairment and depression which are seen with isotretinoin. Denifanstat should also provide better adherence to treatment compared to topical therapies: an estimated 30% to 40% of patients do not adhere to their topical treatments[1]. Denifanstat is licensed from Sagimet Biosciences Inc. (Nasdaq: SGMT) for exclusive rights in Greater China. "The Phase III clinical trial results for denifanstat are highly encouraging. The data demonstrate statistically significant improvements in treatment outcomes for moderate-to-severe acne patients, with percent treatment success of 33.2%, total lesion count reduction of 57.4% from baseline, inflammatory and non-inflammatory lesion counts decreasing by 63.5% and 51.9%, respectively, while maintaining a favorable safety and tolerability profile. Denifanstat's first-in-class mechanism targeting FASN directly addresses a key cause for acne, establishing it as a groundbreaking therapeutic approach in acne treatment." said Prof. Leihong Xiang, Chief Physician of Dermatological Department, Huashan Hospital, Fudan University, Executive Deputy Director of Institute of Dermatology, Fudan University, Deputy Director of Dermatology Division of Chinese Medical Doctor Association and principal investigator of denifanstat Phase III trial for moderate to severe acne. [1] Purvis CG, Balogh EA, Feldman SR. Clascoterone: How the Novel Androgen Receptor Inhibitor Fits Into the Acne Treatment Paradigm. Ann Pharmacother. 2021;55(10):1297-1299. doi:10.1177/1060028021992055. Table 1. Baseline characteristics of Phase III trial of denifanstat Baseline characteristics 50 mg denifanstat, oral, oncedaily (n=240) Placebo, oral, once daily (n=240) Total lesion count 102.2 102.1 Inflammatory lesion count 42.1 43.1 IGA=3 (moderate), % 85.8 85.8 IGA=4 (severe), % 14.2 14.2 Table 2. Efficacy endpoints of 50 mg denifanstat oral, once daily at week 12 versus placebo (intent-to-treat, ITT, analysis) Efficacy endpoints (1) 50 mg denifanstat, oral, once daily (n=240) Placebo, oral,once daily (n=240) Placebo adjusted p value Percent treatment success (2) (primary endpoint) 33.2 14.6 18.6 <0.0001 Percent reduction from baseline in total lesion count (primary endpoint) 57.4 35.4 22.0 <0.0001 Percent reduction from baseline ininflammatory lesion count (primary endpoint) 63.5 43.2 20.3 <0.0001 Percent reduction from baseline in non-inflammatory lesion count (key secondary endpoint) 51.9 28.9 23.0 <0.0001 Absolute reduction from baseline intotal lesion count (secondary endpoint) 58.3 36.2 22.1 <0.0001 Absolute reduction from baseline in inflammatory lesion count (secondaryendpoint) 26.6 18.4 8.2 <0.0001 Notes: (1) All efficacy endpoints are least square means.(2) Treatment success is defined as an Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) with at least a 2-point decrease in IGA from baseline at week 12. Table 3. Denifanstat compared to other commonly used acne treatments (not head-to-head comparison) Category Denifanstat (n=240) Sarecycline(1) (n=1002) Doxycycline(2) (n=216) Clascoterone cream(3) (n=722) Baseline characteristics Total lesion count 102.2 72.4 71.7 103.6 Inflammatory lesion count 42.1 30.0 33.6 42.7 IGA=3 (moderate), % 85.8 85.2 93.5 82.7 IGA=4 (severe), % 14.2 14.9 6.5 17.3 Efficacy endpoints at week 12 Placebo-adjusted percenttreatment success 18.6 9.4 6.7 11.6 Placebo-adjusted percent reductionfrom baseline in total lesion count 22.0 NA 7.6 11.9 Placebo-adjusted percent reductionfrom baseline in inflammatorylesion count 20.3 15.6 7.3 12.8 Placebo-adjusted percent reduction from baseline in non-inflammatorylesion count 23.0 4.5 NA 11.4 Notes: (1) The sarecycline data represent an analysis of its two Phase III clinical trials, with values expressed as means. The data are from Moore, A., et al., J Drugs Dermatol 2018 Vol. 17 Issue 9 Pages 987-996. The non- inflammatory lesion count data are from FDA ( The doxycycline data at week 16 are from Moore, A., et al., J Drugs Dermatol 2015 Vol. 14 Issue 6 Pages 581-6.(3) The clascoterone cream (1%) data represent an analysis of its two Phase III clinical trials, with values expressed as means. The data are from Hebert. A, et al., JAMA Dermatology 2020 Vol. 156 Issue 6, DOI: 10.1001/jamadermatol.2020.0465. About Ascletis Pharma Inc. Ascletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange ( covering the entire value chain from discovery and development to GMP manufacturing. Led by a management team with deep expertise and a proven track record, Ascletis is focused on metabolic diseases by addressing unmet medical needs from a global perspective. Ascletis has multiple clinical stage drug candidates in its metabolic disease pipeline. For more information, please visit Contact: Peter VozzoICR Healthcare443-231-0505 (U.S.) Ascletis Pharma Inc. PR and IR teams+86-181-0650-9129 (China)pr@ ir@ View original content: SOURCE Ascletis Pharma Inc. Sign in to access your portfolio
Bloomberg
4 hours ago
- Bloomberg
Trump Taps Former Small Business Chief for Role Overseeing CFIUS
President Donald Trump has nominated Chris Pilkerton, the acting head of the Small Business Administration during his first term, to oversee a committee charged with screening foreign investments into the US as well as outbound investments in foreign countries, with a close eye on competition with China. Pilkerton has been nominated to serve as the assistant secretary of the Treasury for Investment Security, according to the congressional record. In that role, he will oversee the Committee on Foreign Investment in the US, or CFIUS. The Treasury did not immediately respond to a request for comment.
